Welcome Message
 
Our Company
 
Awards & Recognition
 
Corporate Governance
 
Management Council
Board of Directors
Reports of Insider Transactions
Committee Charters
Corporate Governance Guidelines
Additional Policies and Guidelines
Codes of Conduct
Articles of Incorporation (PDF)
Bylaws (PDF)
 
Compliance & Ethics
 
Our Websites
 
Business Links

 

  » BMS.com Home » About Us » Corporate Governance » Brian Daniels, M.D.
SEARCH INDEX
 





Brian Daniels, M.D.

Senior Vice President, Global Development & Medical Affairs

Brian Daniels, M.D.Brian Daniels is senior vice president, Global Development and Medical Affairs, and a member of the Management Council, the company’s most senior leadership group. In this position, he helps drive the company’s focus on science and medicine as a central strategy of our next-generation BioPharma vision.

Pharmaceutical R&D is a long and complex process,” says Brian. “My role is to make the internal workings as simple as possible so that good, bright people can make substantial contributions to patient care. Our goal is to produce medicines that change the standard of care in a meaningful way for physicians, provide economic value to payers and, most importantly, extend and enhance the lives of patients.”

Brian joined Bristol-Myers Squibb in 2000 as vice president of the Immunology, Pulmonary, and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including ORENCIA and belatacept.

In 2002, Brian was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including REYATAZ and BARACLUDE. He also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations. He was appointed senior vice president, Global Clinical Development in 2004, and to his current position in March 2008.

Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laboratories in clinical research, where he held the role of senior director, Pulmonary and Immunology. He has also worked in clinical research at Genentech.

Brian is married and has a son, 18, and a daughter, 16. Next to spending time with his family, what he enjoys most is gardening. “It’s sort of like simplified drug development,” he says. “It takes a lot of careful tending to develop a great garden. But when you’re successful, it’s a beautiful thing.”

Brian holds bachelor’s and master’s degrees in biology from the Massachusetts Institute of Technology and a medical degree from Washington University School of Medicine. He received training in internal medicine at New York Hospital and in rheumatology at the University of California in San Francisco.

May, 2008




[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2009 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

 

SEARCH INDEX